Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...

The disposition of screened and randomized patients is shown in online appendix Figure 1 (available at https://care.diabetesjournals.org). For the 741 patients randomized to treatments, groups were ...

As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...

Januvia (sitagliptin) is a medication for type 2 diabetes. Along with diet and exercise, it can help lower blood sugar levels. Medicare Part D will generally cover prescription drugs, like Januvia.

CAMBRIDGE, Mass., Jan. 18, 2024 /PRNewswire/ --NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

COPENHAGEN, June 26 (Reuters) - Novo Nordisk said on Saturday extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and also weight reduction than ...